EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

CAR T Cells and T-Cell Therapies for Cancer

Jennifer N Brudno, Marcela V Maus, Christian S Hinrichs

JAMA · 10.12.2024 · 332 (22) · 1924

DOI: 10.1001/jama.2024.19462 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAMA, erschienen am 10.12.2024. Verfasst von Jennifer N Brudno und 2 weiteren Autor:innen. Beteiligte Einrichtung: Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes, Hematologic Neoplasms. Die Arbeit wurde bisher 400-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Chimeric antigen receptor (CAR) T cells are T lymphocytes that are genetically engineered to express a synthetic receptor that recognizes a tumor cell surface antigen and causes the T cell to kill the tumor cell. CAR T treatments improve overall survival for patients with large B-cell lymphoma and progression-free survival for patients with multiple myeloma. Observations Six CAR T-cell products are approved by the US Food and Drug Administration (FDA) for 6 hematologic malignancies: B-cell acute lymphoblastic leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Compared with standard chemotherapy followed by stem cell transplant, CAR T cells improved 4-year overall survival in patients with large B-cell lymphoma (54.6% vs 46.0%). Patients with pediatric acute lymphoblastic leukemia achieved durable remission after CAR T-cell therapy. At 3-year follow-up, 48% of patients were alive and relapse free. In people with multiple myeloma treated previously with 1 to 4 types of non–CAR T-cell therapy, CAR T-cell therapy prolonged treatment-free remissions compared with standard treatments (in 1 trial, CAR T-cell therapy was associated with progression-free survival of 13.3 months compared with 4.4 months with standard therapy). CAR T-cell therapy is associated with reversible acute toxicities, such as cytokine release syndrome in approximately 40% to 95% of patients, and neurologic disorders in approximately 15% to 65%. New CAR T-cell therapies in development aim to increase efficacy, decrease adverse effects, and treat other types of cancer. No CAR T-cell therapies are FDA approved for solid tumors, but recently, 2 other T lymphocyte–based treatments gained approvals: 1 for melanoma and 1 for synovial cell sarcoma. Additional cellular therapies have attained responses for certain solid tumors, including pediatric neuroblastoma, synovial cell sarcoma, melanoma, and human papillomavirus–associated cancers. A common adverse effect occurring with these T lymphocyte–based therapies is capillary leak syndrome, which is characterized by fluid retention, pulmonary edema, and kidney dysfunction. Conclusions and Relevance CAR T-cell therapy is an FDA-approved therapy that has improved progression-free survival for multiple myeloma, improved overall survival for large B-cell lymphoma, and attained high rates of cancer remission for other hematologic malignancies such as acute lymphoblastic leukemia, follicular lymphoma, and mantle cell lymphoma. Recently approved T lymphocyte–based therapies demonstrated the potential for improved outcomes in solid tumor malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesHematologic NeoplasmsHumansReceptors, Antigen, T-CellTranslational Research, Biomedical

Substanzen

Receptors, Antigen, T-CellReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Department of Medicine, Massachusetts General Hospital Cancer Center, Boston.
  • Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence, Rutgers Cancer Institute of New Jersey, New Brunswick.

Förderung

  • NCI NIH HHS

Zitieren

APA

Brudno, J. N., Maus, M. V., & Hinrichs, C. S. (2024). CAR T Cells and T-Cell Therapies for Cancer. JAMA, 332(22), 1924. https://doi.org/10.1001/jama.2024.19462

Vancouver

Brudno JN, Maus MV, Hinrichs CS. CAR T Cells and T-Cell Therapies for Cancer. JAMA. 2024;332(22):1924. doi:10.1001/jama.2024.19462

BibTeX
@article{Brudno2024,
  author = {Brudno, Jennifer N and Maus, Marcela V and Hinrichs, Christian S},
  title = {CAR T Cells and T-Cell Therapies for Cancer},
  journal = {JAMA},
  year = {2024},
  volume = {332},
  number = {22},
  pages = {1924},
  doi = {10.1001/jama.2024.19462}
}
Kostenlos starten →